
Microbot Medical (MBOT) Stock Forecast & Price Target
Microbot Medical (MBOT) Analyst Ratings
Bulls say
Microbot Medical Inc. is positioned for growth within a total addressable market of 2.5 million annual peripheral endovascular procedures in the U.S., highlighting significant potential for market expansion. The LIBERTY Endovascular Robotic System offers enhanced procedure efficiency, cost reduction, and improved quality of care, making it an attractive option for both patients and healthcare providers. Additionally, a notable achievement is the mean 92% relative reduction in radiation exposure for operators compared to traditional methods, underscoring the system's advanced safety features and technological superiority.
Bears say
Microbot Medical Inc faces significant risks that may hinder its stock performance, primarily due to slower than expected commercial uptake of its LIBERTY Endovascular Robotic System. This risk is compounded by factors such as the overall market size, penetration rate, and competitive pressures within the medical device industry. Additionally, potential dilution risk poses a concern for investors, which could further negatively impact stock valuation.
This aggregate rating is based on analysts' research of Microbot Medical and is not a guaranteed prediction by Public.com or investment advice.
Microbot Medical (MBOT) Analyst Forecast & Price Prediction
Start investing in Microbot Medical (MBOT)
Order type
Buy in
Order amount
Est. shares
0 shares